SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance.

ABSTRACT: Metabolic reprogramming in prostate cancer has been widely recognized as a promoter of tumor progression and treatment resistance. This study investigated its association with ferroptosis resistance in prostate cancer and explored its therapeutic potential. In this study, we identified differences in the epithelial characteristics between normal prostate tissue and tissues of various types of prostate cancer using single-cell sequencing. Through transcription factor regulatory network analysis, we focused on the candidate transcription factor, SREBF1. We identified the differences in SREBF1 transcriptional activity and its association with ferroptosis, and further verified this association using hdWGCNA. We constructed a risk score based on SREBF1 target genes associated with the biochemic

SUBMITTER: Wei G 

PROVIDER: S-EPMC11847930 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature